ARTICLE | Finance
Sonoma tops off series A as it builds broader Treg therapy pipeline
Janssen vet Dragone hired as CMO
October 1, 2020 1:30 AM UTC
With an extra $30 million in series A funding, Sonoma is expanding the range of indications for its immunosuppressive Treg cell therapy pipeline, and exploring combination strategies that account for the immune system’s complexity.
The company, which launched in February with a $40 million series A round, announced Wednesday it has now raised a total of $70 million from investors including Lyell Immunopharma Inc., Arch Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund, Milky Way Ventures and other undisclosed investors...